A Public Forum for Human Embryonic Stem Cell Research and Regenerative Medicine Start-Up
Tuesday, June 12, 2012
Clinically-Grade Human Myocardial Grafts Directed from Biologics-Free Human Embryonic Stem Cells for Heart Repair
San
Diego Regenerative Medicine Institute, Xcelthera, La Jolla IVF, and Sanford
Consortium for Regenerative Medicine announce the publication of collaborative original research, titled “Defining Conditions for
Sustaining Epiblast Pluripotence Enables Direct Induction of
Clinically-Suitable Human Myocardial Grafts from Biologics-Free Human Embryonic
Stem Cells”. To date, lacking of a clinically-suitable human cardiac cell
source with adequate myocardium regenerative potential has been the major
setback in regenerating the damaged human heart. Pluripotent human
embryonic stem cells (hESCs) proffer unique revenue to generate a large supply
of cardiac lineage-committed cells as human myocardial grafts for cell-based
therapy. Due to the prevalence of heart disease worldwide and acute shortage of
donor organs or human myocardial grafts, there is
intense interest in developing hESC-based therapy for heart disease and failure.
However, realizing the therapeutic potential of hESCs has been hindered by the
inefficiency and instability of generating cardiac cells from pluripotent cells
through uncontrollable multi-lineage differentiation.
In addition, the need for foreign biologics for derivation, maintenance, and
differentiation of hESCs may make direct use of such cells and their
derivatives in patients problematic. Understanding
the requirements for sustaining pluripotentce and self-renewal of hESCs will provide the foundation for de novo derivation and long-term maintenance of biologics-free
hESCs under optimal yet well-defined culture conditions from which they can be
efficiently directed towards clinically-relevant lineages for cell therapies.
We previously reported the resolving of the elements of a defined
culture system, serving as a platform for effectively directing pluripotent
hESCs uniformly towards a cardiac lineage-specific
fate by small molecule induction. In this
study, we found that, under the defined culture conditions, primitive
endoderm-like (PEL) cells constitutively emerged and acted through the
activin-A-SMAD pathway in a paracrine fashion to sustain the epiblast
pluripotence of hESCs. Such defined conditions enable the spontaneous unfolding
of inherent early embryogenesis processes that, in turn, aid efficient
clonal propagation and de novo derivation of stable
biologics-free hESCs from blastocysts that can be directly differentiated into
a large supply of clinically-suitable human myocardial grafts across the spectrum of developmental stages using small
molecule induction for cardiovascular repair. This
original research article of Parsons et al was
published in Journal of Clinic. Exp. Cardiology Special
Issue on Heart Transplantation.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment